Grail is on a mission to have its cancer blood test become a core part of U.S. screening for a range of tumors. Now, it’s detailing its latest data as it heads to the FDA. Back in June, Grail revealed ...

Forbes contributors publish independent expert analyses and insights. Jesse Pines is an expert in healthcare innovation and wellness. This voice experience is generated by AI. Learn more. This voice ...

A blood-based biomarker test, PancreaSure, demonstrated high sensitivity and specificity in differentiating patients with early-stage pancreatic ductal adenocarcinoma (PDAC) from control individuals ...

A new study suggests that a single blood sample could soon detect multiple cancers, including liver, stomach, and lung cancer ...

Capillary blood tests measure p-tau217, GFAP, and NfL without strict temperature controls or immediate centrifugation. Primary care physicians currently have a diagnostic accuracy of ~61% for ...

Cancerguard detects multiple cancers early by identifying specific DNA and protein markers in a blood sample. The test is available for adults aged 50-84 without cancer in the past three years, but it ...

FIT outperformed cfDNA in detecting advanced precancerous colorectal lesions, showing higher sensitivity and specificity. Blood-based tests offer easier implementation and potentially higher adherence ...

Researchers suggest their approach has the potential to transform early disease detection and health monitoring across diverse clinical settings.

Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. Some companies now offer multi-cancer early detection ...

Firms like Function Health and Oura market regular blood tests to people wanting to take their health into their own hands.